• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

Introduction to 3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide (CAS No. 1004644-61-4)

3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide, with the CAS number 1004644-61-4, is a compound that has garnered significant attention in recent years due to its potential applications in various fields, particularly in medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a nitro group and a hydrazide moiety, making it a valuable candidate for the development of novel therapeutic agents.

The chemical structure of 3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide consists of a pyrazole ring substituted with a methyl and nitro group, attached to a propanehydrazide chain. The presence of these functional groups imparts specific chemical and biological properties to the molecule, which are crucial for its potential therapeutic applications. The nitro group, for instance, can undergo reduction to form amino derivatives, which may exhibit enhanced biological activity. The hydrazide moiety, on the other hand, can participate in various chemical reactions, such as the formation of hydrazones and semicarbazones, which are known to have diverse biological activities.

Recent studies have explored the biological activities of 3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide and its derivatives. One notable area of research is its potential as an anti-inflammatory agent. In vitro studies have shown that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, which are key mediators of inflammation. This property makes it a promising candidate for the treatment of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

In addition to its anti-inflammatory properties, 3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide has also been investigated for its antimicrobial activity. Research has demonstrated that this compound exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria. The mechanism of action is believed to involve the disruption of bacterial cell membranes, leading to cell death. This makes it a potential candidate for the development of new antibiotics to combat drug-resistant bacterial infections.

The potential antiviral activity of 3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide has also been explored. Studies have shown that this compound can inhibit the replication of several viruses, including herpes simplex virus (HSV) and human immunodeficiency virus (HIV). The antiviral mechanism is thought to involve the inhibition of viral enzymes and the disruption of viral entry into host cells. These findings suggest that this compound could be further developed as a broad-spectrum antiviral agent.

In the context of cancer research, 3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide has shown promise as an anticancer agent. Preclinical studies have demonstrated that this compound can induce apoptosis in various cancer cell lines, including breast cancer, lung cancer, and colon cancer cells. The mechanism of action involves the activation of caspase-dependent pathways and the generation of reactive oxygen species (ROS), which lead to cell death. These findings highlight the potential of this compound as a novel anticancer agent.

The pharmacokinetic properties of 3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide have also been studied to assess its suitability for therapeutic use. In vivo studies have shown that this compound has good oral bioavailability and favorable pharmacokinetic parameters, such as a reasonable half-life and low clearance rate. These properties are essential for ensuring that the compound reaches its target site in sufficient concentrations to exert its therapeutic effects.

Toxicity studies have been conducted to evaluate the safety profile of 3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide. In animal models, this compound has shown low toxicity at therapeutic doses, with no significant adverse effects observed on major organs such as the liver and kidneys. These findings suggest that it has a favorable safety profile, making it suitable for further clinical development.

In conclusion, 3-(5-methyl-4-nitro-1H-pyrazol-1-y)propanehydrazide (CAS No. 1004644-61-4) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in various fields, including anti-inflammatory agents, antimicrobial agents, antiviral agents, and anticancer agents. Ongoing research is expected to uncover additional applications and optimize its therapeutic potential.

• 959271-76-2(3-(3,5-Dimethyl-4-nitro-1H-pyrazol-1-yl)-2-methylpropanehydrazide)
• 1005656-29-0(N-Cyclopropyl-3-(5-methyl-4-nitro-pyrazol-1-yl)-propionamide)
• 90091-28-4(3-(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)propanoic acid)
• 1006962-55-5(3-(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)propan-1-amine)
• 1004644-57-8(3-(3-methyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide)
• 1004644-54-5(3-(5-methyl-4-nitro-1H-pyrazol-1-yl)propanoic acid)
• 514800-91-0(2-(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)acetohydrazide)
• 512810-12-7(3-(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)propanehydrazide)
• 1005608-85-4(<br>3-(3-methyl-4-nitro-1H-pyrazol-1-yl)-1-(4-methyl-1H-pyrazol-1-yl)propan-1-o ne)
• 1001500-30-6(1-Ethyl-5-methyl-4-nitro-1H-pyrazole)